Dr. Spencer Lindeman possesses 4 years of industry experience in drug discovery and development. In his current role as Director of Medicinal Chemistry, his research focuses on optimizing and expanding Eradivir’s proprietary BAiT platform. Prior to joining Eradivir, Dr. Lindeman worked at Immunome, a biotech led by former Seagen CEO & Founder Clay Siegall. His professional highlights include delivering a drug candidate (IM-3050) that received IND acceptance and being named to SNMMI’s Ones To Watch list in 2025. To date, Dr. Lindeman is listed as an inventor on 9 patents and an author on 6 peer-reviewed publications. He originally trained in Dr. Philip S. Low’s lab, earning his PhD in chemistry with an emphasis on drug discovery in radioligand therapy.